In early January 2026, DISCO Pharmaceuticals announced it had granted Amgen exclusive global rights to develop and ...

According to Citi analysts, Amgen’s acquisition of Dark Blue could further drive the strength of Amgen’s early oncology ...

Amgen is getting down with Disco Pharmaceuticals, commissioning the German outfit to work on cancer therapies focused on a ...

Amgen is adding Dark Blue to its tapestry, embedding the U.K. biotech’s preclinical blood cancer program into its ...

The acquisition is centered on Dark Blue Therapeutics' small-molecule degrader of the MLLT1 and MLLT3 proteins, which is ...

Amgen (AMGN) ended the recent trading session at $330.05, demonstrating a -3.39% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.01%.

The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that ...

Amgen has bought cancer biotech Dark Blue Therapeutics in a deal that could be worth as much as $840mn, marking the latest ...

Amgen Inc. has acquired cancer drug developer Dark Blue Therapeutics Ltd. in a deal worth as much as $840 million, expanding ...

Amgen Inc.'s latest bid to knock out patents a Kansas-based company alleges the blockbuster osteoporosis drug Evenity ...

Amgen’s acquisition of Dark Blue Therapeutics adds a first-in-class leukemia program that aligns with the company’s growing ...

Amgen is committed to reducing drug costs, expanding its AmgenNow program, and investing in US manufacturing to gain tariff ...